Neutrophil-to-lymphocyte ratio and histological type might predict clinical responses to eriburin-based treatment in patients with metastatic breast cancer.

Mayu MyojinYoshiya HorimotoMayuko ItoShigehisa KitanoYumiko IshizukaRitsuko SasakiToshitaka UomoriTakanori HimuroFumi MurakamiKatsuya NakaiKotaro IijimaMitsue Saito

Published in: Breast cancer (Tokyo, Japan) (2020)

Our data revealed that special histological types and high NLR might be factors related to low responsiveness to eribulin-based regimens in patients with MBC.

Keyphrases

metastatic breast cancer
big data
single cell
clinical trial
machine learning
combination therapy
artificial intelligence
replacement therapy
study protocol